SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Venaxis, Inc. and a Lead Plaintiff Deadline of April 3, 2015 -- APPY

NEW YORK, March 24, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company") APPY securities between March 13, 2014 and January 28, 2015.

Click here to learn about the case: http://docs.wongesq.com/APPY-Info-Request-Form-637. There is no cost or obligation to you.

The complaint stems from the Company's January 29, 2015 disclosure that the FDA determined that the APPY1 Test, designed to aid in the identification of patients at low risk for acute appendicitis, "did not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission." The disclosure followed months of positive statements by the Company regarding the APPY1 Test.

If you suffered a loss in Venaxis you have until April 3, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/APPY-Info-Request-Form-637.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.